Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
A new phase 3 study will test Anktiva in PD-(L)1-relapsed lung cancer.
The synthetic lethality specialist licenses in its second ADC in six months.
Subcutaneous Opdivo joins Tecentriq Hybreza to round out 2024.
Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.
US approval gives Pfizer the first and second-line settings.
But, like Merck two weeks ago, GSK has failed to hit overall survival.
